Knockdown of the ACTN4 gene, which is highly expressed in the exosomes of patients with CRPC (desmoplasia-resistant prostate cancer), reduces prostate cancer cell invasion and proliferation, and may improve the prognosis of limited and advanced prostate cancer as well as predict treatment resistance and tumor recurrence in patients with fatal disease. This evidence concerns the gene ACTN4 and neoplasm.